Name | 4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]aniline |
---|---|
Synonyms |
SC5110
Benzenamine, 4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]- 4-[4-(4-Methyl-1-piperazinyl)-1-piperidinyl]aniline 4-[4-(4-Methyl-piperazin-1-yl)-piperidin-1-yl]-phenylamine 4-(4-(4-Methylpiperazin-1-yl)piperidin-1-yl)aniline |
Density | 1.1±0.1 g/cm3 |
---|---|
Boiling Point | 447.2±45.0 °C at 760 mmHg |
Molecular Formula | C16H26N4 |
Molecular Weight | 274.404 |
Flash Point | 220.6±23.5 °C |
Exact Mass | 274.215759 |
PSA | 35.74000 |
LogP | 0.14 |
Vapour Pressure | 0.0±1.1 mmHg at 25°C |
Index of Refraction | 1.595 |
HS Code | 2933599090 |
---|
~% 959795-70-1 |
Literature: Astex Therapeutics Ltd. Patent: US2009/318441 A1, 2009 ; Location in patent: Page/Page column 45 ; |
Precursor 1 | |
---|---|
DownStream 0 |
HS Code | 2933599090 |
---|---|
Summary | 2933599090. other compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |